Abbott Laboratories (ABT)
Abbott Laboratories on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, federal contracts, earnings dates and insider trades. Listed on NYSE, classified by the SEC as pharmaceutical preparations.
17.4M
Short interest
settlement 2026-10-15
1.8
Days to cover
+0.3 days vs prior
56.9%
Short share of volume
2026-11-02
15
Fails to deliver
settlement 2026-10-13
Thu 21 Jan
Next earnings
estimated date
-$46.9M
Insider flow, 90 days
0 buys, 4 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in ABT is 17,386,736 shares, down 2,524,463 shares over the last month. Over the last 48 readings it ranged from 12,052,833 shares (15 November 2024) to 24,846,147 shares (15 July 2026). At the reported average volume of 9.8M shares a day that is 1.8 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/abt" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 17,386,736 | +27.5% | 9,768,072 | 1.78 |
| 2026-09-30 | 13,634,256 | -31.5% | 9,340,141 | 1.46 |
| 2026-09-15 | 19,911,199 | -10.0% | 7,733,955 | 2.57 |
| 2026-08-31 | 22,129,750 | +8.6% | 8,303,321 | 2.67 |
| 2026-08-14 | 20,375,133 | -9.9% | 7,134,921 | 2.86 |
| 2026-07-31 | 22,624,184 | -8.9% | 13,625,912 | 1.66 |
| 2026-07-15 | 24,846,147 | +6.2% | 11,611,821 | 2.14 |
| 2026-06-30 | 23,387,895 | +6.4% | 15,812,969 | 1.48 |
| 2026-06-15 | 21,974,266 | -0.3% | 12,404,150 | 1.77 |
| 2026-05-29 | 22,044,423 | -5.1% | 11,365,242 | 1.94 |
| 2026-05-15 | 23,222,031 | +3.0% | 13,666,024 | 1.70 |
| 2026-04-30 | 22,536,486 | +3.6% | 15,012,964 | 1.50 |
| 2026-04-15 | 21,746,613 | -8.7% | 9,641,304 | 2.26 |
| 2026-03-31 | 23,825,745 | +19.4% | 15,276,581 | 1.56 |
| 2026-03-13 | 19,950,568 | +9.4% | 8,811,599 | 2.26 |
| 2026-02-27 | 18,233,629 | +6.0% | 8,251,333 | 2.21 |
| 2026-02-13 | 17,198,525 | -8.2% | 11,350,842 | 1.52 |
| 2026-01-30 | 18,726,478 | -6.0% | 17,855,046 | 1.05 |
| 2026-01-15 | 19,914,580 | +14.4% | 6,014,646 | 3.31 |
| 2025-12-31 | 17,399,553 | +9.6% | 5,794,927 | 3.00 |
| 2025-12-15 | 15,875,548 | -14.1% | 5,633,010 | 2.82 |
| 2025-11-28 | 18,485,281 | -3.4% | 8,229,621 | 2.25 |
| 2025-11-14 | 19,141,411 | -5.1% | 5,291,928 | 3.62 |
| 2025-10-31 | 20,171,849 | +4.2% | 6,116,704 | 3.30 |
| 2025-10-15 | 19,360,135 | +6.6% | 6,914,984 | 2.80 |
| 2025-09-30 | 18,168,908 | +0.5% | 5,717,866 | 3.18 |
| 2025-09-15 | 18,072,584 | +1.8% | 5,139,189 | 3.52 |
| 2025-08-29 | 17,753,634 | +3.8% | 4,507,472 | 3.94 |
| 2025-08-15 | 17,110,418 | -6.6% | 6,118,814 | 2.80 |
| 2025-07-31 | 18,325,255 | -3.8% | 9,700,489 | 1.89 |
| 2025-07-15 | 19,057,306 | -1.9% | 5,058,116 | 3.77 |
| 2025-06-30 | 19,425,728 | -6.6% | 7,138,972 | 2.72 |
| 2025-06-13 | 20,799,869 | +3.5% | 4,722,010 | 4.40 |
| 2025-05-30 | 20,092,245 | -9.7% | 6,775,738 | 2.97 |
| 2025-05-15 | 22,256,461 | +5.4% | 6,407,869 | 3.47 |
| 2025-04-30 | 21,115,934 | -2.6% | 7,273,293 | 2.90 |
| 2025-04-15 | 21,691,365 | -0.5% | 8,180,613 | 2.65 |
| 2025-03-31 | 21,794,639 | -0.4% | 6,965,505 | 3.13 |
| 2025-03-14 | 21,877,008 | -4.6% | 8,320,551 | 2.63 |
| 2025-02-28 | 22,932,064 | +2.8% | 5,833,190 | 3.93 |
| 2025-02-14 | 22,311,682 | +22.3% | 5,770,708 | 3.87 |
| 2025-01-31 | 18,239,173 | +21.9% | 9,242,653 | 1.97 |
| 2025-01-15 | 14,968,960 | +4.5% | 4,868,228 | 3.07 |
| 2024-12-31 | 14,317,431 | +18.3% | 5,059,409 | 2.83 |
| 2024-12-13 | 12,100,780 | -10.8% | 4,426,568 | 2.73 |
| 2024-11-29 | 13,568,339 | +12.6% | 4,903,932 | 2.77 |
| 2024-11-15 | 12,052,833 | -14.4% | 5,604,120 | 2.15 |
| 2024-10-31 | 14,073,057 | +0.6% | 5,448,462 | 2.58 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of ABT volume is 56.9%, up 5.9 points over the last five sessions. Over the last 30 readings it ranged from 24.8% (7 October 2026) to 59.9% (25 September 2026). The latest reading sits at the top of that range. The latest reading is 12.5 points above the 30-session average of 44.4%, on 3.4M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 1.9M | 3.4M | 56.9% | 2,466 |
| 2026-10-30 | 1.9M | 3.1M | 59.7% | 1,334 |
| 2026-10-29 | 1.1M | 3.5M | 31.5% | 11,165 |
| 2026-10-28 | 992K | 2.3M | 43.0% | 997 |
| 2026-10-27 | 1.2M | 2.3M | 52.6% | 1,875 |
| 2026-10-26 | 1.6M | 3.2M | 51.0% | 3,597 |
| 2026-10-23 | 1.5M | 4.2M | 36.5% | 4,662 |
| 2026-10-22 | 2.1M | 4.4M | 48.4% | 7,288 |
| 2026-10-21 | 4.5M | 8.9M | 50.3% | 3,946 |
| 2026-10-20 | 2.7M | 5.1M | 54.0% | 1,825 |
| 2026-10-19 | 929K | 3.3M | 27.9% | 4,905 |
| 2026-10-16 | 1.2M | 3.3M | 34.8% | 727 |
| 2026-10-15 | 1.5M | 3.8M | 40.3% | 3,509 |
| 2026-10-14 | 987K | 2.5M | 40.1% | 8,028 |
| 2026-10-13 | 1.3M | 3.8M | 34.7% | 2,606 |
| 2026-10-12 | 1.0M | 2.4M | 43.0% | 934 |
| 2026-10-09 | 1.1M | 2.8M | 37.6% | 1,821 |
| 2026-10-08 | 1.3M | 2.6M | 50.5% | 1,076 |
| 2026-10-07 | 705K | 2.8M | 24.8% | 4,181 |
| 2026-10-06 | 1.4M | 2.8M | 50.6% | 6,654 |
| 2026-10-05 | 1.8M | 3.4M | 54.5% | 14,900 |
| 2026-10-02 | 1.3M | 3.2M | 39.4% | 2,261 |
| 2026-10-01 | 1.3M | 3.3M | 39.3% | 1,373 |
| 2026-09-30 | 938K | 2.5M | 38.0% | 5,180 |
| 2026-09-29 | 1.2M | 2.9M | 43.4% | 4,009 |
| 2026-09-28 | 1.1M | 2.2M | 49.1% | 1,523 |
| 2026-09-25 | 1.8M | 2.9M | 59.9% | 770 |
| 2026-09-24 | 971K | 2.2M | 43.2% | 7,165 |
| 2026-09-23 | 2.7M | 5.6M | 48.8% | 2,490 |
| 2026-09-22 | 1.4M | 3.0M | 46.6% | 3,135 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 13 October 2026, the fails-to-deliver balance in ABT is 15 shares, down 3 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (21 September 2026) to 1,714,305 shares (22 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-13 | 15 | $101.82 | $2K |
| 2026-10-09 | 18 | $98.49 | $2K |
| 2026-10-08 | 789 | $98.73 | $78K |
| 2026-10-06 | 33 | $100.10 | $3K |
| 2026-10-01 | 60 | $98.83 | $6K |
| 2026-09-28 | 32 | $101.29 | $3K |
| 2026-09-21 | 1 | $102.61 | $103 |
| 2026-09-02 | 17,701 | $108.93 | $1.9M |
| 2026-08-31 | 300 | $112.47 | $34K |
| 2026-08-24 | 20,890 | $116.64 | $2.4M |
| 2026-08-20 | 28 | $114.43 | $3K |
| 2026-08-17 | 1,200 | $111.25 | $134K |
| 2026-08-13 | 106 | $110.91 | $12K |
| 2026-08-10 | 3,200 | $107.81 | $345K |
| 2026-08-06 | 7,500 | $105.71 | $793K |
| 2026-08-05 | 10,155 | $105.46 | $1.1M |
| 2026-08-03 | 440 | $105.70 | $47K |
| 2026-07-30 | 2,249 | $108.00 | $243K |
| 2026-07-27 | 170 | $103.06 | $18K |
| 2026-07-22 | 1,029 | $99.67 | $103K |
| 2026-07-20 | 24,900 | $100.68 | $2.5M |
| 2026-07-17 | 100 | $98.83 | $10K |
| 2026-07-16 | 84 | $89.27 | $7K |
| 2026-07-10 | 177 | $94.40 | $17K |
| 2026-07-09 | 208,947 | $95.18 | $19.9M |
| 2026-07-06 | 21,124 | $95.40 | $2.0M |
| 2026-07-02 | 23 | $92.18 | $2K |
| 2026-07-01 | 64 | $90.74 | $6K |
| 2026-06-29 | 12,621 | $94.12 | $1.2M |
| 2026-06-22 | 1,714,305 | $88.41 | $151.6M |
Insider trades
SEC Form 4, newest first. JSONInsiders at ABT reported 4 open-market sells worth $46.9M in the last 90 days and no open-market buys. Latest filing: Conroy Kevin T (Director) on 2026-09-23.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-23 | Conroy Kevin T | Director | Tax withholding | 53K | $103.99 | $5.5M | 81K |
| 2026-09-02 | MCCOY JOHN A. JR. | VICE PRESIDENT AND CONTROLLER | Sell | 27 | $109.54 | $3K | 25K |
| 2026-09-01 | Boudreau Philip P | EVP AND CFO | Tax withholding | 388 | $110.36 | $43K | 71K |
| 2026-09-01 | MCCOY JOHN A. JR. | VICE PRESIDENT AND CONTROLLER | Tax withholding | 52 | $110.36 | $6K | 25K |
| 2026-08-25 | Ford Robert B | CHAIRMAN AND CEO | Sell | 180K | $116.19 | $20.9M | 306K |
| 2026-08-25 | Ford Robert B | CHAIRMAN AND CEO | Sell | 219K | $115.57 | $25.3M | 487K |
| 2026-08-25 | Ford Robert B | CHAIRMAN AND CEO | Exercise or conversion | 247K | $59.94 | $14.8M | 705K |
| 2026-08-25 | Ford Robert B | CHAIRMAN AND CEO | Exercise or conversion | 152K | $44.40 | $6.7M | 458K |
| 2026-08-12 | Morrone Louis H. | EXECUTIVE VICE PRESIDENT | Discretionary trade | 12 | $107.99 | $1K | 0 |
| 2026-08-11 | Morrone Louis H. | EXECUTIVE VICE PRESIDENT | Sell | 6K | $109.83 | $643K | 71K |
| 2026-06-30 | Morrone Louis H. | EXECUTIVE VICE PRESIDENT | Tax withholding | 269 | $92.71 | $25K | 77K |
| 2026-06-27 | Cushman Elizabeth C. | EVP, GC AND SECRETARY | Tax withholding | 560 | $94.12 | $53K | 38K |
| 2026-05-07 | Stratton John G | Director | Buy | 2K | $86.82 | $174K | 23K |
| 2026-04-28 | Moreland Mary K | EXECUTIVE VICE PRESIDENT | Discretionary trade | 5K | $94.41 | $502K | 17K |
| 2026-04-27 | STARKS DANIEL J | Director | Buy | 10K | $92.65 | $927K | 6.8M |
| 2026-04-24 | Ahuja Nita | Director | Grant | 2K | $0.00 | $0 | 2K |
| 2026-04-24 | Gonzalez Patricia Paola | Director | Grant | 2K | $0.00 | $0 | 9K |
| 2026-04-24 | McDew Darren W | Director | Grant | 2K | $0.00 | $0 | 13K |
| 2026-04-24 | Babineaux-Fontenot Claire | Director | Grant | 2K | $0.00 | $0 | 8K |
| 2026-04-24 | Kumbier Michelle | Director | Grant | 2K | $0.00 | $0 | 18K |
| 2026-04-24 | Roman Michael F | Director | Grant | 2K | $0.00 | $0 | 11K |
| 2026-04-24 | Blount Sally E. | Director | Grant | 2K | $0.00 | $0 | 36K |
| 2026-04-24 | O'Grady Michael | Director | Grant | 2K | $0.00 | $0 | 8K |
| 2026-04-24 | Stratton John G | Director | Grant | 2K | $0.00 | $0 | 21K |
| 2026-04-24 | Conroy Kevin T | Director | Grant | 2K | $0.00 | $0 | 134K |
| 2026-04-24 | McKinstry Nancy | Director | Grant | 2K | $0.00 | $0 | 41K |
| 2026-04-24 | STARKS DANIEL J | Director | Grant | 2K | $0.00 | $0 | 6.7M |
| 2026-04-23 | Boudreau Philip P | EVP AND CFO | Buy | 2K | $91.50 | $201K | 2K |
| 2026-04-23 | Boudreau Philip P | EVP AND CFO | Discretionary trade | 9K | $92.04 | $820K | 9K |
| 2026-03-23 | ORVILLE JACOB A | Senior Vice President | Grant | 13K | $0.00 | $0 | 50K |
| 2026-03-02 | Cushman Elizabeth C. | EVP, GC AND SECRETARY | Sell | 263 | $115.58 | $30K | 39K |
| 2026-03-02 | Shroff Eric | Senior Vice President | Sell | 709 | $115.58 | $82K | 39K |
| 2026-03-02 | Morrone Louis H. | EXECUTIVE VICE PRESIDENT | Sell | 1K | $115.58 | $132K | 77K |
| 2026-03-02 | Moreland Mary K | EXECUTIVE VICE PRESIDENT | Sell | 613 | $115.58 | $71K | 104K |
| 2026-03-02 | MCCOY JOHN A. JR. | VICE PRESIDENT AND CONTROLLER | Sell | 585 | $115.58 | $68K | 25K |
| 2026-03-02 | Salvadori Daniel Gesua Sive | EVP AND GROUP PRESIDENT | Sell | 885 | $115.58 | $102K | 146K |
| 2026-02-27 | Cushman Elizabeth C. | EVP, GC AND SECRETARY | Tax withholding | 1K | $116.26 | $165K | 39K |
| 2026-02-27 | Shroff Eric | Senior Vice President | Tax withholding | 1K | $116.26 | $161K | 40K |
| 2026-02-27 | Morrone Louis H. | EXECUTIVE VICE PRESIDENT | Tax withholding | 4K | $116.26 | $470K | 78K |
| 2026-02-27 | Boudreau Philip P | EVP AND CFO | Tax withholding | 7K | $116.26 | $865K | 71K |
| 2026-02-27 | Moreland Mary K | EXECUTIVE VICE PRESIDENT | Tax withholding | 5K | $116.26 | $538K | 105K |
| 2026-02-27 | Scoggins Christopher J | EXECUTIVE VICE PRESIDENT | Tax withholding | 5K | $116.26 | $581K | 77K |
| 2026-02-27 | MCCOY JOHN A. JR. | VICE PRESIDENT AND CONTROLLER | Tax withholding | 1K | $116.26 | $133K | 25K |
| 2026-02-27 | Salvadori Daniel Gesua Sive | EVP AND GROUP PRESIDENT | Tax withholding | 7K | $116.26 | $769K | 147K |
| 2026-02-27 | Ford Robert B | CHAIRMAN AND CEO | Tax withholding | 30K | $116.26 | $3.5M | 306K |
| 2026-02-27 | Earnhardt Lisa D | EVP AND GROUP PRESIDENT | Tax withholding | 9K | $116.26 | $997K | 90K |
| 2026-02-24 | Cushman Elizabeth C. | EVP, GC AND SECRETARY | Grant | 15K | $0.00 | $0 | 40K |
| 2026-02-24 | Shroff Eric | Senior Vice President | Grant | 11K | $0.00 | $0 | 41K |
| 2026-02-24 | Morrone Louis H. | EXECUTIVE VICE PRESIDENT | Grant | 15K | $0.00 | $0 | 82K |
| 2026-02-24 | Boudreau Philip P | EVP AND CFO | Grant | 28K | $0.00 | $0 | 79K |
| 2026-02-24 | Moreland Mary K | EXECUTIVE VICE PRESIDENT | Grant | 14K | $0.00 | $0 | 110K |
| 2026-02-24 | Scoggins Christopher J | EXECUTIVE VICE PRESIDENT | Grant | 19K | $0.00 | $0 | 82K |
| 2026-02-24 | MCCOY JOHN A. JR. | VICE PRESIDENT AND CONTROLLER | Grant | 5K | $0.00 | $0 | 26K |
| 2026-02-24 | Salvadori Daniel Gesua Sive | EVP AND GROUP PRESIDENT | Grant | 22K | $0.00 | $0 | 154K |
| 2026-02-24 | Ford Robert B | CHAIRMAN AND CEO | Grant | 83K | $0.00 | $0 | 337K |
| 2026-02-24 | Earnhardt Lisa D | EVP AND GROUP PRESIDENT | Grant | 27K | $0.00 | $0 | 99K |
| 2026-02-04 | STARKS DANIEL J | Director | Buy | 5K | $108.33 | $545K | 6.7M |
| 2026-02-04 | STARKS DANIEL J | Director | Buy | 5K | $109.14 | $542K | 6.7M |
| 2026-01-23 | Ford Robert B | CHAIRMAN AND CEO | Buy | 19K | $107.13 | $2.0M | 216K |
| 2025-12-11 | Salvadori Daniel Gesua Sive | EVP AND GROUP PRESIDENT | Gift | 2K | $123.28 | $189K | 132K |
| 2025-11-25 | Shroff Eric | Senior Vice President | Sell | 2K | $128.02 | $203K | 30K |
| 2025-09-01 | MCCOY JOHN A. JR. | VICE PRESIDENT AND CONTROLLER | Tax withholding | 79 | $132.66 | $10K | 21K |
| 2025-09-01 | Boudreau Philip P | EVP AND CFO | Tax withholding | 387 | $132.66 | $51K | 51K |
| 2025-08-08 | Boudreau Philip P | EVP AND CFO | Sell | 6K | $134.55 | $747K | 51K |
| 2025-06-30 | Morrone Louis H. | EXECUTIVE VICE PRESIDENT | Tax withholding | 269 | $134.38 | $36K | 67K |
| 2025-06-27 | Cushman Elizabeth C. | EVP, GC AND SECRETARY | Grant | 4K | $0.00 | $0 | 25K |
| 2025-04-30 | Blount Sally E. | Director | Sell | 3K | $129.66 | $337K | 34K |
| 2025-04-25 | Alpern Robert J | Director | Grant | 2K | $0.00 | $0 | 41K |
| 2025-04-25 | Babineaux-Fontenot Claire | Director | Grant | 2K | $0.00 | $0 | 5K |
| 2025-04-25 | Blount Sally E. | Director | Grant | 2K | $0.00 | $0 | 37K |
| 2025-04-25 | Gonzalez Patricia Paola | Director | Grant | 2K | $0.00 | $0 | 7K |
| 2025-04-25 | Kumbier Michelle | Director | Grant | 2K | $0.00 | $0 | 16K |
| 2025-04-25 | McDew Darren W | Director | Grant | 2K | $0.00 | $0 | 10K |
| 2025-04-25 | McKinstry Nancy | Director | Grant | 2K | $0.00 | $0 | 39K |
| 2025-04-25 | O'Grady Michael | Director | Grant | 2K | $0.00 | $0 | 5K |
| 2025-04-25 | Roman Michael F | Director | Grant | 2K | $0.00 | $0 | 8K |
| 2025-04-25 | STARKS DANIEL J | Director | Grant | 2K | $0.00 | $0 | 6.7M |
| 2025-04-25 | Stratton John G | Director | Grant | 2K | $0.00 | $0 | 19K |
| 2025-03-07 | Earnhardt Lisa D | EVP AND GROUP PRESIDENT | Exercise or conversion | 200 | $80.98 | $16K | 72K |
| 2025-03-07 | Earnhardt Lisa D | EVP AND GROUP PRESIDENT | Sell | 200 | $136.65 | $27K | 72K |
| 2025-03-06 | Earnhardt Lisa D | EVP AND GROUP PRESIDENT | Sell | 91K | $133.82 | $12.2M | 72K |
| 2025-03-06 | Earnhardt Lisa D | EVP AND GROUP PRESIDENT | Exercise or conversion | 91K | $80.98 | $7.4M | 163K |
| 2025-03-03 | MCCOY JOHN A. JR. | VICE PRESIDENT AND CONTROLLER | Sell | 562 | $138.17 | $78K | 21K |
| 2025-03-03 | Moreland Mary K | EXECUTIVE VICE PRESIDENT | Sell | 791 | $138.17 | $109K | 96K |
| 2025-03-03 | Morrone Louis H. | EXECUTIVE VICE PRESIDENT | Sell | 1K | $138.17 | $154K | 67K |
| 2025-03-03 | Shroff Eric | Senior Vice President | Sell | 562 | $138.17 | $78K | 32K |
| 2025-03-03 | Wainer Andrea F | RETIRED EVP | Sell | 949 | $138.17 | $131K | 74K |
| 2025-02-28 | ALLEN HUBERT L | EXECUTIVE VICE PRESIDENT, GC | Tax withholding | 8K | $135.87 | $1.1M | 192K |
| 2025-02-28 | Boudreau Philip P | EVP AND CFO | Tax withholding | 5K | $135.87 | $667K | 57K |
| 2025-02-28 | Earnhardt Lisa D | EVP AND GROUP PRESIDENT | Tax withholding | 8K | $135.87 | $1.1M | 72K |
| 2025-02-28 | Ford Robert B | CHAIRMAN AND CEO | Tax withholding | 32K | $135.87 | $4.3M | 253K |
| 2025-02-28 | MCCOY JOHN A. JR. | VICE PRESIDENT AND CONTROLLER | Tax withholding | 1K | $135.87 | $149K | 22K |
| 2025-02-28 | Moreland Mary K | EXECUTIVE VICE PRESIDENT | Tax withholding | 6K | $135.87 | $761K | 96K |
| 2025-02-28 | Morrone Louis H. | EXECUTIVE VICE PRESIDENT | Tax withholding | 4K | $135.87 | $596K | 68K |
| 2025-02-28 | Salvadori Daniel Gesua Sive | EVP AND GROUP PRESIDENT | Tax withholding | 8K | $135.87 | $1.1M | 134K |
| 2025-02-28 | Wainer Andrea F | RETIRED EVP | Tax withholding | 7K | $135.87 | $994K | 75K |
| 2025-02-25 | ALLEN HUBERT L | EXECUTIVE VICE PRESIDENT | Grant | 15K | $0.00 | $0 | 200K |
| 2025-02-25 | Boudreau Philip P | EXECUTIVE VICE PRESIDENT | Grant | 22K | $0.00 | $0 | 61K |
| 2025-02-25 | Earnhardt Lisa D | EXECUTIVE VICE PRESIDENT | Grant | 19K | $0.00 | $0 | 80K |
| 2025-02-25 | Ford Robert B | CHAIRMAN AND CEO | Grant | 65K | $0.00 | $0 | 285K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON12 Form 144 notices on file for ABT worth $50.9M at the prices reported; 3 in the last 90 days worth $46.8M. Latest: John A. McCoy, Jr. filed on 2026-09-02 to sell 27 shares ($3K) from 2026-09-02.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-02 | John A. McCoy, Jr.Officer | 27 | $3K | 0.000% | 2026-09-02 | UBS Financial Services, Inc. |
| 2026-08-25 | Robert B. FordOfficer, Director | 399K | $46.2M | 0.023% | 2026-08-25 | UBS Financial Services, Inc. |
| 2026-08-11 | Louis H. MorroneOfficer | 6K | $643K | 0.000% | 2026-08-11 | UBS Financial Services, Inc. |
| 2026-05-15 | Robert J. AlpernRetired Director | 8K | $647K | 0.000% | 2026-05-15 | Janney Montgomery Scott LLC |
| 2026-04-27 | Robert J. AlpernRetired Director | 29K | $2.7M | 0.002% | 2026-04-27 | UBS Financial Services, Inc. |
| 2026-03-02 | Elizabeth C. CushmanOfficer | 263 | $30K | 0.000% | 2026-03-02 | UBS Financial Services, Inc. |
| 2026-03-02 | Eric ShroffOfficer | 709 | $82K | 0.000% | 2026-03-02 | UBS Financial Services, Inc. |
| 2026-03-02 | Louis H. MorroneOfficer | 1K | $132K | 0.000% | 2026-03-02 | UBS Financial Services, Inc. |
| 2026-03-02 | Mary K. MorelandOfficer | 613 | $71K | 0.000% | 2026-03-02 | UBS Financial Services, Inc. |
| 2026-03-02 | John A. McCoy, Jr.Officer | 585 | $68K | 0.000% | 2026-03-02 | UBS Financial Services, Inc. |
| 2026-03-02 | Daniel Gesua Sive SalvadoriOfficer | 885 | $102K | 0.000% | 2026-03-02 | UBS Financial Services, Inc. |
| 2025-11-25 | Eric ShroffOfficer | 2K | $203K | 0.000% | 2025-11-25 | UBS Financial Services, Inc. |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON1 holder reports 5% or more of ABT in its latest filing, on Schedule 13G (passive). The holder is Vanguard Capital Management at 7.5% of the class (130,676,776 shares), filed 2026-04-29 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-04-29 | 13G | Vanguard Capital Managementinvestment adviser | 130.7M | 7.5% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 12 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
13F holders
Tracked managers holding ABT at their latest 13F. JSON10 of the 30 tracked managers held ABT at their latest 13F, $2.62B in total at quarter-end prices. Citadel Advisors is the largest at $780.1M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Citadel Advisors | 2026-06-30 | 8.6M | $780.1M | 0.09% | +6.7M |
| Two Sigma Investments | 2026-06-30 | 8.1M | $737.4M | 0.53% | +1.7M |
| AQR Capital Management | 2026-06-30 | 4.2M | $380.5M | 0.13% | +2.6M |
| Millennium Management | 2026-06-30 | 3.6M | $326.7M | 0.12% | +2.3M |
| Point72 Asset Management | 2026-06-30 | 1.6M | $140.8M | 0.16% | new |
| D. E. Shaw & Co. | 2026-06-30 | 1.5M | $132.3M | 0.06% | -3.8M |
| Renaissance Technologies | 2026-06-30 | 686K | $62.3M | 0.09% | -552K |
| Fisher Asset Management | 2026-06-30 | 505K | $45.9M | 0.01% | -247K |
| Bridgewater Associates | 2026-06-30 | 60K | $5.4M | 0.02% | -57K |
| Soros Fund Management | 2026-06-30 | 45K | $4.1M | 0.05% | 0 |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q1 FY 2026 (quarter ended 2026-03-31) Abbott Laboratories reported revenue of $11.16B, up 7.8% from the same quarter a year earlier, and net income of $1.08B (0.61 diluted EPS). In FY 2025 it generated $9.57B of operating cash flow and spent $893.0M on buybacks and $4.12B on dividends. As of 2026-03-31, cash was $6.80B against $29.64B of debt.
- Cash
- $6.80B
- Debt
- $29.64B
- Equity
- $52.06B
- Total assets
- $110.43B
- Shares outstanding
- 1,741,812,429
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q1 FY 2026 | 2026-03-31 | $11.16B | $1.08B | 9.6% | 0.61 |
| Q4 FY 2025derived | 2025-12-31 | $11.46B | $1.78B | 15.5% | n/a |
| Q3 FY 2025 | 2025-09-30 | $11.37B | $1.64B | 14.5% | 0.94 |
| Q2 FY 2025 | 2025-06-30 | $11.14B | $1.78B | 16.0% | 1.01 |
| Q1 FY 2025 | 2025-03-31 | $10.36B | $1.32B | 12.8% | 0.76 |
| Q4 FY 2024derived | 2024-12-31 | $10.97B | $9.23B | 84.1% | n/a |
| Q3 FY 2024 | 2024-09-30 | $10.63B | $1.65B | 15.5% | 0.94 |
| Q2 FY 2024 | 2024-06-30 | $10.38B | $1.30B | 12.5% | 0.74 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $44.33B | $6.52B | $9.57B | $2.17B | $893.0M | $4.12B |
| FY 2024 | 2024-12-31 | $41.95B | $13.40B | $8.56B | $2.21B | $1.29B | $3.84B |
| FY 2023 | 2023-12-31 | $40.11B | $5.72B | $7.26B | $2.20B | $1.23B | $3.56B |
| FY 2022 | 2022-12-31 | $43.65B | $6.93B | $9.58B | $1.78B | $3.79B | $3.31B |
| FY 2021 | 2021-12-31 | $43.08B | $7.07B | $10.53B | $1.89B | $2.30B | $3.20B |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-03-31; shares outstanding as of 2026-03-31 from the cover page.
Federal contracts
The largest contract actions for Abbott Laboratories and its subsidiaries. JSON67 contract actions on file for ABT: $45.4M obligated in the last 90 days and $54.2M in the last 12 months across 4 awarding agencies. The largest was $3.0M from the Department of Veterans Affairs on 2026-09-17 (chemistry analyzers, reagents, consumables and controls option year 3). This covers the largest contract actions, not every award, and agencies report late.
| Action date | Agency | Amount | Type | Description |
|---|---|---|---|---|
| 2026-10-30 | Department of Veterans AffairsDepartment of Veterans Affairs | $1.2M | mod P00001delivery order | ALINITY TEST KITSUSAspending |
| 2026-10-29 | Department of Veterans AffairsDepartment of Veterans Affairs | $159K | new awardbpa call | VISN 6 POINT OF CARE I-STAT BLOOD ANALYZERS - OY3USAspending |
| 2026-10-29 | Department of Veterans AffairsDepartment of Veterans Affairs | $136K | new awardbpa call | VISN 6 POINT OF CARE I-STAT BLOOD ANALYZERS - OY3USAspending |
| 2026-10-29 | Department of Veterans AffairsDepartment of Veterans Affairs | $132K | new awardbpa call | VISN 6 POINT OF CARE I-STAT BLOOD ANALYZERS - OY3USAspending |
| 2026-10-27 | Department of Veterans AffairsDepartment of Veterans Affairs | $284K | mod P00015delivery order | ABBOTT ARCHITECT CPRRUSAspending |
| 2026-10-26 | Department of Veterans AffairsDepartment of Veterans Affairs | $57K | mod P00004purchase order | EO 14398 ABBOTT ENSITE SERVICE CONTRACTUSAspending |
| 2026-10-26 | Department of JusticeFederal Prison System / Bureau of Prisons | $45K | new awarddelivery order | ABBOTT- FREESTYLE LIBRE 3 SENSORSUSAspending |
| 2026-10-23 | Department of Veterans AffairsDepartment of Veterans Affairs | $89K | new awardbpa call | IMMUNOASSAY ANALYZER AND REAGENTS - OPTION YEAR 3USAspending |
| 2026-10-23 | Department of Veterans AffairsDepartment of Veterans Affairs | $66K | new awardbpa call | N. TX VA ISTAT BPA ORDERUSAspending |
| 2026-10-22 | Department of Veterans AffairsDepartment of Veterans Affairs | $91K | mod P00001bpa call | REOPENER RECONCILIATION PAYMENTUSAspending |
| 2026-10-22 | Department of Veterans AffairsDepartment of Veterans Affairs | $86K | mod P00004purchase order | EXPLORATION EP UNITS SERVICE CONTRACTUSAspending |
| 2026-10-22 | Department of Veterans AffairsDepartment of Veterans Affairs | $67K | mod P00001bpa call | VISN 04 CHEMISTRY TESTING | RECONCILIATION PAYMENT - MFFPUSAspending |
| 2026-10-22 | Department of Veterans AffairsDepartment of Veterans Affairs | $53K | mod P00002bpa call | RECONCILIATION REOPENER PAYMENTUSAspending |
| 2026-10-21 | Department of Veterans AffairsDepartment of Veterans Affairs | $108K | new awarddelivery order | TRICLIP G5 SYSTEMUSAspending |
| 2026-10-20 | Department of Health and Human ServicesIndian Health Service | $276K | mod P00004delivery order | INTEGRATED CHEMISTRY SYSTEM FOR FEDERAL HOSPITALSUSAspending |
| 2026-10-20 | Department of Veterans AffairsDepartment of Veterans Affairs | $119K | new awardbpa call | COST-PER-TEST (CPT) BLANKET PURCHASE AGREEMENT FOR POINT OF CARE (POC) TESTING EQUIPMENT, REAGENTS AND SUPPLIES FOR THE OVERTON BROOKS VA MEDICAL CENTER- EO 14398USAspending |
| 2026-10-20 | Department of Veterans AffairsDepartment of Veterans Affairs | $106K | mod P00003purchase order | ABBOTT CARDIAC SERVICE & MAINTENANCE - IC EO 14398USAspending |
| 2026-10-14 | Department of Veterans AffairsDepartment of Veterans Affairs | $120K | mod P00001purchase order | EO 14398USAspending |
| 2026-10-14 | Department of Veterans AffairsDepartment of Veterans Affairs | $48K | mod P00006definitive contract | EO 14398 MOLECULAR ANALYZER PREVENTATIVE MAINTENANCE SERVICEUSAspending |
| 2026-10-13 | Department of Veterans AffairsDepartment of Veterans Affairs | $834K | new awarddelivery order | TASK ORDER FUNDING 3MO BRIDGE AMBULANCE SERVICESUSAspending |
| 2026-10-13 | Department of Veterans AffairsDepartment of Veterans Affairs | $168K | mod P00003purchase order | ELECTROPHYSIOLOGY LAB EQUIPMENT SERVICEUSAspending |
| 2026-10-09 | Department of Veterans AffairsDepartment of Veterans Affairs | $48K | mod P00001purchase order | EO 14398-OPTIS MOBILE SYSTEM SERVICE OY1USAspending |
| 2026-10-07 | Department of Veterans AffairsDepartment of Veterans Affairs | $1000K | mod P00001delivery order | REAGENTS AND CONSUMABLES FOR LABORATORY TESTS.USAspending |
| 2026-10-07 | Department of Veterans AffairsDepartment of Veterans Affairs | $334K | new awarddelivery order | COST PER TESTUSAspending |
| 2026-10-06 | Department of Veterans AffairsDepartment of Veterans Affairs | $920K | new awardbpa call | ALINITY M REAGENTUSAspending |
| 2026-10-02 | Department of Veterans AffairsDepartment of Veterans Affairs | $1.9M | new awarddelivery order | LAB COST PER TESTUSAspending |
| 2026-10-02 | Department of Veterans AffairsDepartment of Veterans Affairs | $1.4M | new awardbpa call | CPRR CHEMISTRYUSAspending |
| 2026-10-02 | Department of Veterans AffairsDepartment of Veterans Affairs | $31K | new awardbpa call | ISTAT ANALYZER LEASE + CREATININE CARTRIDGESUSAspending |
| 2026-10-02 | Department of Veterans AffairsDepartment of Veterans Affairs | $17K | new awardbpa call | GLUCOMETER LEASE AND REAGENTSUSAspending |
| 2026-10-01 | Department of Veterans AffairsDepartment of Veterans Affairs | $2.9M | new awarddelivery order | EXERCISE ORDERING PERIODUSAspending |
| 2026-10-01 | Department of Veterans AffairsDepartment of Veterans Affairs | $2.1M | new awarddelivery order | EXERCISE ORDERING PERIODUSAspending |
| 2026-10-01 | Department of Veterans AffairsDepartment of Veterans Affairs | $1.9M | new awarddelivery order | AUTOMATED CHEMISTRY LABORATORY COST PER TESTUSAspending |
| 2026-10-01 | Department of Veterans AffairsDepartment of Veterans Affairs | $1.8M | mod P00008delivery order | ABBOTT ALINITY M REAGENTS AND CONSUMABLES OY3USAspending |
| 2026-10-01 | Department of Veterans AffairsDepartment of Veterans Affairs | $1.6M | new awardbpa call | TVHS NASHVILLE CAMPUS ORDER AGAINST THE VISN ABBOTT IMMUNOCHEMISTRY LAB BPA.USAspending |
| 2026-10-01 | Department of Veterans AffairsDepartment of Veterans Affairs | $1.6M | new awardbpa call | YR 4 TOUSAspending |
| 2026-10-01 | Department of Veterans AffairsDepartment of Veterans Affairs | $1.5M | mod P00004delivery order | ::CHEMISTRY ANALYZERS::USAspending |
| 2026-10-01 | Department of Veterans AffairsDepartment of Veterans Affairs | $1.5M | new awardbpa call | MEMPHIS VAMC OY1 ABBOTT IMMUNOCHEMISTRY LAB BPA ORDER.USAspending |
| 2026-10-01 | Department of Veterans AffairsDepartment of Veterans Affairs | $1.4M | new awardbpa call | EL PASO VETERANS HEALTH CARE SYSTEM IMMUNOASSAY COST-PER-REPORTABLE RESULT (CPRR)USAspending |
| 2026-10-01 | Department of Veterans AffairsDepartment of Veterans Affairs | $1.4M | new awardbpa call | JAMES H. QUILLEN OY1 ORDER AGAINST THE ABBOTT IMMUNOCHEMISTRY LAB BPA.USAspending |
| 2026-10-01 | Department of Veterans AffairsDepartment of Veterans Affairs | $1.3M | mod P00003delivery order | CHEMISTRY COST-PER-REPORTABLE-RESULT BRIDGE IS INCLUSIVE OF ABBOTT DIAGNOSTICS EQUIPMENT, REAGENTS, CONSUMABLES, SERVICE, TRAINING, AND STANDARD SHIPPING.USAspending |
What this page is
Abbott Laboratories in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Abbott Laboratories (ABT), SEC CIK 1800, listed on NYSE, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-13.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-02.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-04-29.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-03-31.JSON and CSV
- Federal contracts
- USAspending.govSource: USAspending.gov.The largest contract actions each day, as agencies report them (up to 90 days late). Latest 2026-10-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-10-21.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-23.JSON and CSV
- Company record
- EDGAR filing index for CIK 1800Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of ABT is sold short?
17,386,736 shares were held short at the 2026-10-15 settlement, 1.8 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is ABT's daily short volume?
On 2026-11-02, 1,932,919 of the 3,400,129 ABT shares reported to FINRA were sold short, 56.9% of the day's reported volume. Short volume is a flow for one day, not a position.
Does ABT have fails to deliver?
The SEC's latest file shows 15 ABT shares failed to deliver at settlement 2026-10-13. Fails are reported per settlement date and published twice a month with a lag.
Are ABT insiders buying or selling?
Insiders at ABT reported 4 open-market sells worth $46.9M in the last 90 days and no open-market buys. Latest filing: Conroy Kevin T (Director) on 2026-09-23.
Have ABT insiders filed to sell?
12 Form 144 notices on file for ABT worth $50.9M at the prices reported; 3 in the last 90 days worth $46.8M. Latest: John A. McCoy, Jr. filed on 2026-09-02 to sell 27 shares ($3K) from 2026-09-02.
Who owns 5% or more of ABT?
1 holder reports 5% or more of ABT in its latest filing, on Schedule 13G (passive). The holder is Vanguard Capital Management at 7.5% of the class (130,676,776 shares), filed 2026-04-29 for an event on 2026-03-31.
What did ABT report last quarter?
In Q1 FY 2026 (quarter ended 2026-03-31) Abbott Laboratories reported revenue of $11.16B, up 7.8% from the same quarter a year earlier, and net income of $1.08B (0.61 diluted EPS). In FY 2025 it generated $9.57B of operating cash flow and spent $893.0M on buybacks and $4.12B on dividends. As of 2026-03-31, cash was $6.80B against $29.64B of debt.
Which tracked 13F managers own ABT?
10 of the 30 tracked 13F managers held ABT shares at their latest filing, $2.62B in all. The largest: Ken Griffin's Citadel Advisors (8.6M shares, $780.1M), Two Sigma Investments (8.1M shares, $737.4M), Cliff Asness's AQR Capital Management (4.2M shares, $380.5M), Izzy Englander's Millennium Management (3.6M shares, $326.7M), Steve Cohen's Point72 Asset Management (1.6M shares, $140.8M), D. E. Shaw & Co. (1.5M shares, $132.3M). The table above lists all 10.
How much federal contract money did ABT receive?
$45.4M was obligated to Abbott Laboratories and its subsidiaries in the last 90 days and $54.2M in the last 12 months, counting the largest contract actions on USAspending, not every award. Obligations are not revenue; they are spent over each contract's life.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.